Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

Amgen is dealing with the threat of several fast-approaching patent expirations. The drugmaker's dividend streak is ...

Amgen plans to continue with Phase 3 studies for MariTide and other conditions in 2025. These developments reflect Amgen’s ongoing efforts in advancing its oncology and obesity treatment pipelines.

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...

The GLP-1 arena has turned into a boxing match between heavyweights Novo Nordisk and Eli Lilly as the two pharma giants ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ...

Find the latest analyst research, reports, and ratings for Amgen Inc. Common Stock (AMGN) at Nasdaq.com.